Select Publications
Book Chapters
2020, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 333 - 343, http://dx.doi.org/10.1007/978-3-030-48363-0_17
,2020, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 383 - 393, http://dx.doi.org/10.1007/978-3-030-48363-0_19
,2016, 'Merkel Cell Carcinoma', in Surgical Oncology Manual, Springer International Publishing, pp. 189 - 196, http://dx.doi.org/10.1007/978-3-319-26276-5_14
,2016, 'Non-melanoma Skin Cancer', in Surgical Oncology Manual, Springer International Publishing, pp. 225 - 232, http://dx.doi.org/10.1007/978-3-319-26276-5_17
,Journal articles
2024, 'Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma', Cancer Letters, 586, http://dx.doi.org/10.1016/j.canlet.2024.216633
,2024, 'A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.', Journal of Clinical Oncology, 42, pp. 4 - 4, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.4
,2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190
,2024, 'PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results.', Journal of Clinical Oncology, 42, pp. 123 - 123, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.123
,2024, 'Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.', Journal of Clinical Oncology, 42, pp. TPS249 - TPS249, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps249
,2024, 'Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.', Journal of Clinical Oncology, 42, pp. TPS250 - TPS250, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps250
,2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, http://dx.doi.org/10.1007/s00280-023-04636-2
,2024, 'Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial', The Lancet Oncology, 25, pp. 99 - 107, http://dx.doi.org/10.1016/S1470-2045(23)00529-6
,2023, 'Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma', New England Journal of Medicine, 389, pp. 2256 - 2266, http://dx.doi.org/10.1056/NEJMoa2304753
,2023, 'Abstract B039: A phase 1/2 study of dendrimer-enhanced (DEP) SN38 (SN38-SPL9111/DEP irinotecan) in patients with advanced solid tumours', Molecular Cancer Therapeutics, 22, pp. B039 - B039, http://dx.doi.org/10.1158/1535-7163.targ-23-b039
,2023, 'Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617', European Urology Open Science, 57, pp. 30 - 36, http://dx.doi.org/10.1016/j.euros.2023.08.007
,2023, 'Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial', Clinical Cancer Research, 29, pp. 3867 - 3874, http://dx.doi.org/10.1158/1078-0432.CCR-23-0731
,2023, 'Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4–6', European Urology, 84, pp. e94 - e95, http://dx.doi.org/10.1016/j.eururo.2023.04.043
,2023, 'A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer', Clinical Cancer Research, 29, pp. 3292 - 3300, http://dx.doi.org/10.1158/1078-0432.CCR-22-2585
,2023, 'A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations', British Journal of Cancer, 129, pp. 475 - 485, http://dx.doi.org/10.1038/s41416-023-02311-0
,2023, 'Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis', Melanoma Research, 33, pp. 316 - 325, http://dx.doi.org/10.1097/CMR.0000000000000900
,2023, 'Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study', The Lancet Oncology, 24, pp. 925 - 935, http://dx.doi.org/10.1016/S1470-2045(23)00275-9
,2023, 'Extracellular vesicles from biological fluids as potential markers in castration resistant prostate cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4701 - 4717, http://dx.doi.org/10.1007/s00432-022-04391-6
,2023, 'Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects', Journal of Managed Care and Specialty Pharmacy, 29, pp. 758 - 768, http://dx.doi.org/10.18553/jmcp.2023.29.7.758
,2023, 'Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer', Journal of Clinical Oncology, 41, pp. 3339 - 3351, http://dx.doi.org/10.1200/JCO.22.01649
,2023, 'Chemotherapy in Cutaneous Melanoma: Is There Still a Role?', Current Oncology Reports, 25, pp. 609 - 621, http://dx.doi.org/10.1007/s11912-023-01385-6
,2023, 'Circulating ether lipids in prostate cancer.', Journal of Clinical Oncology, 41, pp. e17009 - e17009, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e17009
,2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus 177lutetium-prostate specific membrane antigen-617 (177Lu-PSMA-617) in the LuPARP trial.', Journal of Clinical Oncology, 41, pp. 5064 - 5064, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5064
,2023, 'LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 41, pp. 5005 - 5005, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.5005
,2023, 'Machine learning prediction of patient-reported outcomes associated with systemic therapy from medical records.', Journal of Clinical Oncology, 41, pp. e13564 - e13564, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13564
,2023, 'NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).', Journal of Clinical Oncology, 41, pp. TPS9612 - TPS9612, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.tps9612
,2023, 'Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.', Journal of Clinical Oncology, 41, pp. 3127 - 3127, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.3127
,2023, 'Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress (British Journal of Cancer, (2023), 128, 10, (1791-1793), 10.1038/s41416-023-02199-w)', British Journal of Cancer, 128, pp. 1976, http://dx.doi.org/10.1038/s41416-023-02231-z
,2023, 'LXS196 for Metastatic Uveal Melanoma - finally some progress', British Journal of Cancer, 128, pp. 1791 - 1793, http://dx.doi.org/10.1038/s41416-023-02199-w
,2023, 'Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse', Science Advances, 9, http://dx.doi.org/10.1126/sciadv.adf9063
,2023, 'Abstract CT267: ENB-003, an ETBR antagonist, in combination with pembrolizumab for advanced solid tumor: The ENBolden trial', Cancer Research, 83, pp. CT267 - CT267, http://dx.doi.org/10.1158/1538-7445.am2023-ct267
,2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334, http://dx.doi.org/10.1016/S1470-2045(23)00063-3
,2023, 'Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).', Journal of Clinical Oncology, 41, pp. TPS271 - TPS271, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps271
,2023, 'Performance of a blood-based liquid biopsy test to detect PSMA expression on circulating tumor cells in men with metastatic prostate cancer.', Journal of Clinical Oncology, 41, pp. 256 - 256, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.256
,2023, 'Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).', Journal of Clinical Oncology, 41, pp. TPS296 - TPS296, http://dx.doi.org/10.1200/jco.2023.41.6_suppl.tps296
,2023, 'Advances in the clinical management of uveal melanoma', Nature Reviews Clinical Oncology, 20, pp. 99 - 115, http://dx.doi.org/10.1038/s41571-022-00714-1
,2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398
,2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677
,2023, 'Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma', Ophthalmology Retina, http://dx.doi.org/10.1016/j.oret.2023.10.009
,2023, 'Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231156392
,2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104
,2023, '1127P Efficacy of immune checkpoint inhibitors (ICIs) in advanced mucosal melanoma (MM): A systematic review and meta-analysis', Annals of Oncology, 34, pp. S677 - S677, http://dx.doi.org/10.1016/j.annonc.2023.09.2261
,2023, '1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', Annals of Oncology, 34, pp. S988 - S989, http://dx.doi.org/10.1016/j.annonc.2023.09.2773
,2023, '1831P Dissecting the meaning of obesity in metastatic castration resistant prostate cancer: Size or metabolism?', Annals of Oncology, 34, pp. S991 - S991, http://dx.doi.org/10.1016/j.annonc.2023.09.2779
,2023, '1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)', Annals of Oncology, 34, pp. S1014 - S1014, http://dx.doi.org/10.1016/j.annonc.2023.09.1116
,2023, 'Integrated, Longitudinal Analysis of Cell-free DNA in Uveal Melanoma.', Cancer Res Commun, 3, pp. 267 - 280, http://dx.doi.org/10.1158/2767-9764.CRC-22-0456
,